
Amphastar Pharmaceuticals, Inc.: updates and filings
Price
$29.17
November 16, 2026Market cap $1.2B
What Ploutos Investor adds for Amphastar Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 13, 2026Officer or director changeForm8-K
- Jul 8, 2026Other material eventsForm8-K
- Jun 3, 2026Shareholder voteForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 13, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 13, 2026Additional annual meeting materialFormDEFA14A
- Apr 13, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 16, 2026Other material eventsForm8-K
- Mar 6, 2026Officer or director changeForm8-K
- Mar 6, 2026Material agreement enteredForm8-K
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Jan 12, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Nov 6, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 6, 2025Results of operationsForm8-K
- Oct 24, 2025Material agreement enteredForm8-K
- Oct 17, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 18, 2025Material agreement enteredForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 13, 2026 | 8-K | Officer or director change | Document |
| Jul 8, 2026 | 8-K | Other material events | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 13, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 16, 2026 | 8-K | Other material events | Document |
| Mar 6, 2026 | 8-K | Officer or director change | Document |
| Mar 6, 2026 | 8-K | Material agreement entered | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Jan 12, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Nov 6, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 6, 2025 | 8-K | Results of operations | Document |
| Oct 24, 2025 | 8-K | Material agreement entered | Document |
| Oct 17, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 18, 2025 | 8-K | Material agreement entered | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 11, 2005.
The full analysis
What do Amphastar Pharmaceuticals's filings show?
The filings are where every one of Amphastar Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.